SARMs

AC-262536 is a non-steroidal selective androgen receptor modulator (SARM) with partial agonist activity. It demonstrates tissue-selective anabolic effects while showing significantly reduced androgenic activity compared to full agonists, making it a subject of ongoing scientific interest in the field of androgen receptor pharmacology.

Andarine (S4) is a SARM with high binding affinity for the androgen receptor. It was one of the earliest SARMs developed and has been studied for its anabolic effects on skeletal muscle and bone density. Documented applications include muscle wasting models and osteoporosis studies, with notable selectivity for muscle and bone tissue over androgenic tissues.

Cardarine (GW-501516) is a PPARδ (Peroxisome proliferator-activated receptor delta) agonist, technically not a SARM but often grouped with them. It activates the PPARδ pathway, which regulates genes involved in energy expenditure and lipid metabolism. Scientific focus has covered its role in metabolic syndrome models, endurance studies, and lipid metabolism analysis.

GW0742 is a highly selective PPARδ (PPAR-beta/delta) agonist with greater potency and selectivity than Cardarine (GW-501516). It activates peroxisome proliferator-activated receptor delta pathways involved in lipid oxidation, mitochondrial biogenesis, and anti-inflammatory responses. Applied in investigations into metabolic disorders, cardiovascular biology, and inflammatory disease models.

Ibutamoren (MK-677) is a potent, orally active growth hormone secretagogue. It mimics the action of ghrelin by binding to the ghrelin receptor (GHSR), stimulating the pulsatile release of growth hormone and subsequently increasing IGF-1 levels. Scientific focus covers its applications in growth hormone deficiency models and metabolic studies.

LGD-3033 is a next-generation non-steroidal SARM with high tissue selectivity and binding affinity for the androgen receptor. Structurally distinct from LGD-4033, it has been studied for its anabolic effects on skeletal muscle and bone with reduced androgenic activity. Documented applications include muscle atrophy models, bone density studies, and comparative SARM pharmacology.

Ligandrol (LGD-4033) is a potent, non-steroidal SARM with high selectivity and binding affinity for the androgen receptor. It demonstrates robust anabolic activity in muscle and bone tissue with minimal prostate and sebaceous gland activity. Among the most studied SARMs in clinical settings, with multiple Phase I trials examining safety and pharmacokinetic profiles.

Ostarine (MK-2866) is one of the most studied SARMs, known for its well-characterised tissue selectivity profile. It binds to androgen receptors in muscle and bone tissue with high affinity, demonstrating anabolic effects while exhibiting minimal interaction with androgenic tissues. Extensively analysed in clinical settings for muscle preservation and tissue-selective activity.

SR9009 is a synthetic REV-ERBα agonist that modulates circadian rhythm pathways and metabolic processes. By activating REV-ERB nuclear receptors, it influences the regulation of genes involved in lipid and glucose metabolism, mitochondrial biogenesis, and the body's internal clock. Documented applications include metabolic disorder models and circadian biology studies.

SR9011 is a REV-ERB agonist with high potency and selectivity, structurally related to SR9009. It activates both REV-ERBα and REV-ERBβ receptors, influencing circadian gene expression and metabolic regulation. Preclinical studies have demonstrated effects on fat storage, glucose production, and mitochondrial function.